A 68‑year‑old male patient with small‑cell lung cancer received six cycles of combination therapy with adebrelimab plus etoposide and carboplatin. Following the final administration of the immune-chemotherapy regimen, the patient developed extensive erythema, desquamation and pruritus on the head, face, neck, chest, hands and extremities, accompanied by oral ulceration, and the patient was diagnosed with grade Ⅲ delayed‑onset rash. After infection and other predisposing factors were ruled out, the rash was considered to be adebrelimab‑induced. Symptoms improved after treatment with high‑dose glucocorticoids and antihistamines. The rash relapsed 11 days after tapering of glucocorticoids, and the patient was readmitted. The aforementioned therapeutic regimen was re‑administered, resulting in rash improvement. Glucocorticoid‑induced diabetes mellitus occurred during the treatment course, for which antidiabetic therapy was initiated, and adebrelimab was permanently discontinued. Assessment via the Naranjo's Probability Scale indicated a probable causal relationship between the rash and adebrelimab. This case highlights that prolonged monitoring of cutaneous adverse reactions is warranted during adebrelimab treatment. High‑dose glucocorticoids should be promptly initiated for grade Ⅲ rash, with intensified glucocorticoid dose titration and blood glucose monitoring to reduce the risk of immune-related skin adverse reactions and glucocorticoid-related complications.

1. De VelascoG,JeY,BosseD,et al.Comprehensive Meta-analysis of key immune-related adverse events from CTLA-4 and PD-1/PD-L1 inhibitors in cancer patients[J].Cancer Immunol Res,2017,5 (4):312-318.DOI:10.1158/2326-6066.CIR-16-0237.

2. WangJ,ZhouC,YaoW,et al.Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomized, double-blind, placebo-controlled, phase 3 trial[J].Lancet Oncol,2022,23 (6):739-747.DOI:10.1016/S1470-2045 (22)00224-8.

3. NaranjoCA,BustoU,SellersEM,et al.A method for estimating the probability of adverse drug reactions[J].Clin Pharmacol Ther,1981,30:239-245.DOI:10.1038/clpt.1981.154.

4. EshaqAM,FlanaganTW,BaAbbad AA,et al.Immune checkpoint inhibitor-associated cutaneous adverse events: mechanisms of occurrence[J].Int J Mol Sci,2024,26(1):88.DOI:10.3390/ijms26010088.

5. 凌晓静,魏继福.抗肿瘤药物超敏反应[J].中华临床免疫和变态反应杂志,2023,17(5):464-471.LingXJ,WeiJF.Hypersensitivity reactions to antitumor drugs[J].Chinese Journal of Clinical Immunology and Allergy,2023,17(5):464-471.DOI:10.3969/j.issn.1673-8705.2023.05.012.

6. 中国医师协会微无创医学专业委员会妇科肿瘤学组.妇科肿瘤卡铂化疗所致过敏反应的中国专家共识 (2022年版) [J].肿瘤药学,2022,12(4):413-421.Gynecologic Oncology Group, Professional Committee of Minimally‑invasive and Non‑invasive Medicine, Chinese Medical Doctor Association.Chinese expert consensus on hypersensitivity reactions induced by carboplatin chemotherapy for gynecologic malignancies (2022 edition)[J].Anti‑Tumor Pharmacy,2022,12(4):413‑421.DOI:10.3969/j.issn.2095-1264.2022.04.01.

7. WatanabeT,YamaguchiY.Cutaneous manifestations associated with immune checkpoint inhibitors[J].Front Immunol,2023,14:1071983.DOI:10.3389/fimmu.2023.1071983.

8. ZamoraAE,CrawfordJC,ThomasPG.Hitting the target: how T cells detect and eliminate tumors[J].J Immunol,2018,200 (2):392-399.DOI:10.4049/jimmunol.1701413.

9. WangY,CaoJ,LiuX,et al.Innate immune activation in vitiligo: mechanisms and pathophysiological implications[J].Front Immunol,2025,16:1631074.DOI:10.3389/fimmu.2025.1631074.

10. 中国临床肿瘤学会指南工作委员会, 编著.中国临床肿瘤学会（CSCO）免疫检查点抑制剂相关的毒性管理指南2023[M].北京:人民卫生出版社,2023:26-38.

11. 中华医学会皮肤性病学分会,中国医师协会皮肤科医师分会,中国老年医学学会皮肤医学分会.免疫检查点抑制剂相关皮肤不良反应诊治中国专家共识（2024版）[J].中华医学杂志,2024,104(20):1790-1803.Dermatology and Venereology Branch of Chinese Medical Association,Dermatologist Branch of Chinese Medical Doctor Association,Dermatology Branch of Chinese Geriatrics Society.Chinese expert consensus on diagnosis and treatment of immune checkpoint inhibitor‑related cutaneous adverse reactions (2024 edition)[J].National Medical Journal of China,2024,104(20):1790‑1803.DOI:10.3760/cma.j.cn112137-20240112-00091.

12. KuoAM,MarkovaA.High grade dermatologic adverse events associated with immune checkpoint blockade for cancer[J].Front Med (Lausanne),2022,9:898790.DOI:10.3389/fmed.2022.898790.

13. 中华医学会,中华医学会杂志社,中华医学会皮肤性病学分会,等.药疹基层诊疗指南（2022年）[J].中华全科医师杂志,2022,21(9):804-813.Chinese Medical Association,Chinese Medical Association Publishing House,Dermatology and Venereology Branch of Chinese Medical Association,et al.Primary care guidelines for drug eruption (2022)[J].Chinese Journal of General Practitioners,2022,21(9):804‑813.DOI:10.3760/cma.j.cn114798-20220215-00101.

14. 高梦婷,焦曦,董凤晓,等.免疫检查点抑制剂致严重免疫相关皮肤不良反应的临床特点和诊疗策略研究[J].肿瘤综合治疗电子杂志,2023,9(4):66-77.GaoMT,JiaoX,DongFX,et al.Clinical characteristics and diagnosis‑treatment strategies of severe immune‑related cutaneous adverse reactions induced by immune checkpoint inhibitors[J].Journal of Multidisciplinary Cancer Management (Electronic Version),2023,9(4):66‑77.DOI:10.12151/JMCM.2023.04.

15. GuoM,VanderWaldeAM,YuX,et al.Immune checkpoint inhibitor rechallenge safety and efficacy in stage IV non-small cell lung cancer patients after immune-related adverse events[J].Clin Lung Cancer,2022,23(8):686-693.DOI:10.1016/j.cllc.2022.07.015.

16. InnoA,RovielloG,GhidiniA,et al.Rechallenge of immune checkpoint inhibitors: a systematic review and Meta-analysis[J].Crit Rev Oncol Hematol,2021,165:103434.DOI:10.1016/j.critrevonc.2021.103434.

17. LuY,ZhouL,ZouY,et al.Antibiotic-induced severe cutaneous adverse reactions: a single-center retrospective study over ten years[J].Front Immunol,2024,15:1415830.DOI:10.3389/fimmu.2024.1415830.

18. ShahH,ParisiR,MukherjeeE,et al.Update on Stevens-Johnson syndrome and toxic epidermal necrolysis: diagnosis and management[J].Am J Clin Dermatol,2024,25(6):891-908.DOI:10.1007/s40257-024-00889-6.

19. ChenST,SemenovYR,AllooA,et al.Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy[J].J Immunother Cancer,2024,12(4):007675.DOI:10.1136/jitc-2023-007675.

20. LiC,LiZ,SunQ,et al.Severe cutaneous adverse reactions associated with immune checkpoint inhibitors therapy and anti-VEGF combination therapy: a real-world study of the FDA adverse event reporting system[J].Expert Opin Drug Saf,2024,23(6):777-784.DOI:10.1080/14740338.2023.2251381.

21. SuZ,ZhangL,LianX,et al.Risk factors for cutaneous immune-related adverse events: a systematic scoping review[J].Front Immunol,2026,17:1722781.DOI:10.3389/fimmu.2026.1722781.

22. DanlosFX,VoisinAL,DyevreV,et al.Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease[J].Eur J Cancer,2018,91:21-29.DOI:10.1016/j.ejca.2017.12.008.